Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Ventana to Develop Companion Tests for Incyte, Starting with Phase II IDO1 Inhibitor


Roche Subsidiary Ventana Medical Systems and Incyte announced this week that the two companies have made an agreement under which Ventana will support Incyte's cancer drug development with companion diagnostic tests, beginning with a test for a compound in Incyte's IDO1 inhibitor program.

Incyte's Group Vice President Victor Sandor said in a statement that "with the advancement of INCB24360 into multiple Phase 2 studies, [the company's] first-in-class IDO1 inhibitor program was a logical place to begin to incorporate potential companion diagnostics."

Preclinical studies have shown that inhibition of IDO increases the anti-tumor immune response and dramatically increases the efficacy of various chemotherapeutic agents, according to Incyte.

The company is currently evaluating INCB24360 in an open-label, randomized, Phase II study comparing the drug against tamoxifen in biochemical recurrent-only ovarian cancer patients following complete remission with first-line chemotherapy.

The company also has a second Phase II trial testing INCB024360 in dose escalation followed by a blinded, randomized comparison of INCB024360 and Bristol-Myers Squibb's Yervoy (ipilimumab) versus Yervoy plus placebo in metastatic melanoma patients.

Though Ventana declined to provide details on what other specific cancer therapies in Incyte's pipleline the partners might focus on advancing with a companion test, in the company's statement Ventana President Mara Aspinall said the new partners look forward to pursuing "many successful drug development programs together."

Ventana was unavailable by press time to discuss its strategy for developing companion diagnostic for INCB24360, how such a test would be used within the drug development process, or how it might play into Incyte's plans for eventually gaining FDA approval for the drug.

Roche and Ventana have a strict firewall policy that enables the subsidiary to advance companion tests for Roche's own personalized medicines as well as partner with competitors. According to Ventana, it has worked with more than 45 drug companies over a decade and inked 150 collaborative companion diagnostics projects, most recently a partnership with Boehringer Ingelheim to identify best responders to undisclosed Boehringer oncology treatments (PGx Reporter 9/25/2013)

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.